Genmab: Epcoritamab plus R2 shows consistent benefit across EPCORE FL‑1 subgroups

Trial and analysis

The Phase 3 EPCORE FL‑1 trial randomized 481 relapsed/refractory follicular lymphoma patients to epcoritamab plus rituximab and lenalidomide (R2) (n=243) or R2 alone (n=238). Genmab reported a post‑hoc subgroup analysis presented at EHA 2026 assessing efficacy and tolerability across clinically relevant subgroups including FLIPI (0–2 vs 3–5), POD24 status, and NHL‑5 fitness categories.

Efficacy findings

Progression‑free survival consistently favored epcoritamab+R2, with hazard ratios below 0.3 across analyzed subgroups (FLIPI 0–2 HR 0.18 [0.10–0.33]; FLIPI 3–5 HR 0.25 [0.15–0.42]; POD24 HR 0.22 [0.13–0.37]; NHL‑5 low HR 0.27 [0.17–0.42]; NHL‑5 H+I HR 0.14 [0.06–0.29]). Overall response rates and complete response rates were higher with the combination across risk and fitness categories (examples: FLIPI 0–2 ORR 96.5% vs 84.8%, CRR 86.6% vs 62.1%; FLIPI 3–5 ORR 93.0% vs 72.6%, CRR 77.0% vs 35.4%).

Safety and dosing notes

The safety profile for epcoritamab+R2 was described as manageable and consistent with the overall trial; no new safety signals were identified. The company noted neutropenia and infections were more frequent among patients receiving lower lenalidomide doses and that lenalidomide dose reductions were used in practice to manage adverse events while maintaining benefit.